|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Clinical Care/Education/Nutrition |
Importance of Early Insulin Secretion
Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes
1 Ruth Collins Diabetes Center, Baylor University Medical Center, Dallas, Texas
2 Diabetes and Glandular Disease Clinic, San Antonio, Texas
3 Novartis Pharmaceuticals, East Hanover, New Jersey
OBJECTIVE—This study compared the effects of nateglinide, glyburide, and placebo on postmeal glucose excursions and insulin secretion in previously diet-treated patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS—This randomized, double-blind, placebo-controlled multicenter study was conducted in 152 patients who received either nateglinide (120 mg before three meals daily, n = 51), glyburide (5 mg q.d. titrated to 10 mg q.d. after 2 weeks, n = 50), or placebo (n = 51) for 8 weeks. Glucose, insulin, and C-peptide profiles during liquid meal challenges were measured at weeks 0 and 8. At weeks -1 and 7, 19-point daytime glucose and insulin profiles, comprising three solid meals, were measured.
RESULTS—During the liquid-meal challenge, nateglinide reduced the incremental glucose area under the curve (AUC) more effectively than glyburide (
= -4.94 vs. -2.71 mmol · h/l, P < 0.05), whereas glyburide reduced fasting plasma glucose more effectively than nateglinide ( = -2.9 vs. -1.0 mmol/l, respectively, P < 0.001). In contrast, C-peptide induced by glyburide was greater than that induced by nateglinide ( = +1.83 vs. +0.95 nmol · h/l, P < 0.01), and only glyburide increased fasting insulin levels. During the solid meal challenges, nateglinide and glyburide elicited similar overall glucose control ( 12-h incremental AUC = -13.2 vs. -15.3 mmol · h/l), but the insulin AUC induced by nateglinide was significantly less than that induced by glyburide ( 12-h AUC = +866 vs. +1,702 pmol · h/l, P = 0.01).
CONCLUSIONS—This study demonstrated that nateglinide selectively enhanced early insulin release and provided better mealtime glucose control with less total insulin exposure than glyburide.
Abbreviations: AUC, area under the curve • FPG, fasting plasma glucose
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Shigeto, M. Katsura, M. Matsuda, S. Ohkuma, and K. Kaku Nateglinide and Mitiglinide, but Not Sulfonylureas, Induce Insulin Secretion through a Mechanism Mediated by Calcium Release from Endoplasmic Reticulum J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 1 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Gangji, T. Cukierman, H. C. Gerstein, C. H. Goldsmith, and C. M. Clase A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin Diabetes Care, February 1, 2007; 30(2): 389 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tuomi, E. H. Honkanen, B. Isomaa, L. Sarelin, and L. C. Groop Improved Prandial Glucose Control With Lower Risk of Hypoglycemia With Nateglinide Than With Glibenclamide in Patients With Maturity-Onset Diabetes of the Young Type 3 Diabetes Care, February 1, 2006; 29(2): 189 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]
|
|
|
|
|
|
J. Gerich, P. Raskin, L. Jean-Louis, D. Purkayastha, and M. A. Baron PRESERVE-{beta}: Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin Diabetes Care, September 1, 2005; 28(9): 2093 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Abletshauser, P. Brunel, K.-H. Usadel, and M. Hanefeld Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 93 - 99. [Abstract] [PDF]
|
|
|
|
 |
|
 M. F. Carroll, A. Gutierrez, M. Castro, D. Tsewang, and D. S. Schade Targeting Postprandial Hyperglycemia: A Comparative Study of Insulinotropic Agents in Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5248 - 5254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Eddy and L. Schlessinger Archimedes: A trial-validated model of diabetes Diabetes Care, November 1, 2003; 26(11): 3093 - 3101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Nateglinide and {blacktriangledown}repaglinide for type 2 diabetes? DTB, July 1, 2003; 41(7): 52 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Del Prato, R. J. Heine, L. Keilson, C. Guitard, S. G. Shen, and R. P. Emmons Treatment of Patients Over 64 Years of Age With Type 2 Diabetes: Experience from nateglinide pooled database retrospective analysis Diabetes Care, July 1, 2003; 26(7): 2075 - 2080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Sheehan Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach Clin. Med. Res., July 1, 2003; 1(3): 189 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fonseca, G. Grunberger, S. Gupta, S. Shen, and J. E. Foley Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control Diabetes Care, June 1, 2003; 26(6): 1685 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Saloranta, C. Guitard, E. Pecher, P. de Pablos-Velasco, K. Lahti, P. Brunel, and L. Groop Nateglinide Improves Early Insulin Secretion and Controls Postprandial Glucose Excursions in a Prediabetic Population Diabetes Care, December 1, 2002; 25(12): 2141 - 2146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Carroll, A. Izard, K. Riboni, M. R. Burge, and D. S. Schade Control of Postprandial Hyperglycemia: Optimal use of short-acting insulin secretagogues Diabetes Care, December 1, 2002; 25(12): 2147 - 2152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Saloranta, K. Hershon, M. Ball, S. Dickinson, and D. Holmes Efficacy and Safety of Nateglinide in Type 2 Diabetic Patients with Modest Fasting Hyperglycemia J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4171 - 4176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rosenstock, S. G. Shen, M. R. Gatlin, and J. E. Foley Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes Diabetes Care, September 1, 2002; 25(9): 1529 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Cozma, S. D. Luzio, G. J. Dunseath, K. W. Langendorg, T. Pieber, and D. R. Owens Comparison of the Effects of Three Insulinotropic Drugs on Plasma Insulin Levels After a Standard Meal Diabetes Care, August 1, 2002; 25(8): 1271 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Cohen and B. A. Ramlo-Halsted How Do the New Insulin Secretagogues Compare? Diabetes Care, August 1, 2002; 25(8): 1472 - 1473. [Full Text] [PDF]
|
|
|
|
|
|
A. Schweizer, M. Ball, D. R Owens, F. Cressier, D. O Holmes, and P. Brunel Comparison of the postprandial glucose and insulin profiles with nateglinide and gliclazide in type 2 diabetic patients The British Journal of Diabetes & Vascular Disease, May 1, 2002; 2(3): 228 - 232. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Saleh and G. Grunberger Hypoglycemia: An Excuse for Poor Glycemic Control? Clin. Diabetes, October 1, 2001; 19(4): 161 - 167. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |